Study of daratumumab for severe skin reaction caused by a medicine
Treatments studied
Part of Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a drug called daratumumab, which is usually used for certain cancers, to see if it can help people with a rare but severe skin condition caused by a medicine. The condition causes the top layer of skin to blister and peel off. The study aims to stop the skin from peeling further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a severe skin reaction caused by a medicine, such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
- The skin reaction started less than 7 days ago and is still spreading.
- Your hepatitis B tests are negative.
- You are willing to use contraception if you are able to become pregnant, and you are not pregnant or breastfeeding.
- You are not currently in septic shock (a severe infection affecting your blood pressure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests stem-cell treatment to help people with severe skin reactions called SJS-TEN. It may reduce ongoing skin damage and help recovery when treatment is started soon after symptoms begin.
This trial tests a new device called FreedomEDGE® that gives daratumumab under the skin instead of by an IV. It might make your monthly treatment faster and more comfortable.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
This Phase 1 study tests whether adding daratumumab to standard intensive chemotherapy (idarubicin and cytarabine) works safely in people age 60 or older with a higher-risk form of acute myeloid leukemia (AML). It may help improve outcomes, but the main goal is to find the best dosing and safety in this age group.
This study looks at immune markers and gut/skin bacteria in people with Darier's disease. It aims to better understand the condition, which could lead to better treatments in the future.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Hear when a new Toxic Epidermal Necrolysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.